Aurobindo obtains FDA nod for generic Lanoxin
Aurobindo has received the Food and Drug Administration's clearance for Digoxin in dosage strengths of 0.0625 mg, 0.125 mg and 0.25 mg.
The product is the generic of Concordia’s Lanoxin.
The 0.62mg strength, which is now available, is the first and only generic in the market for this product, the company said.
[Read more: Aurobindo obtains FDA OK for generic Lioresal]
The medication is indicated for the following: treatment of mild to moderate heart failure in adults; increases myocardial contractility in pediatric patients with heart failure; and for the control of ventricular response rate in adult patients with chronic atrial fibrillation.
Digoxin tablets have a market value of roughly $2.1 million for the 12 months ending December 2021, according to IQVIA.